top of page

EXPLORE OUR ARTICLE LIBRARY

Eric D. Donnenfeld, MD: CRST

Blocking the inflammatory cascade with OMIDRIA

Blocking the inflammatory cascade with OMIDRIA
Denise M. Visco, MD, MBA: CRST

Controlling postoperative inflammation with OMIDRIA

Controlling postoperative inflammation with OMIDRIA
Denise M. Visco, MD, MBA: JCRS

Effects of OMIDRIA on postoperative CME, iritis, pain, and photophobia

Effects of OMIDRIA on postoperative CME, iritis, pain, and photophobia
Eric D. Donnenfeld, MD: JCRS

Pain control and reduction of opioid use with OMIDRIA

Pain control and reduction of opioid use with OMIDRIA
Richard S. Davidson, MD

The role of nonopioid alternatives in cataract surgery pain management

The role of nonopioid alternatives in cataract surgery pain management
M. Edward Wilson, MD: The Ophthalmologist

Making Cataract Surgery Child’s Play

Making Cataract Surgery Child’s Play

Authors identified here or in linked articles may be speakers or consultants for Rayner or the previous manufacturer of OMIDRIA.

This page is intended for educational purposes, using scientific exchange around the OMIDRIA experience.

Indications and Usage

OMIDRIA® is added to ophthalmic irrigating solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.

Important Safety Information

OMIDRIA must be added to irrigating solution prior to intraocular use.

OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients.
Systemic exposure to phenylephrine may cause elevations in blood pressure.
Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory drugs (NSAIDs), or have a past medical history of asthma.
The most commonly reported adverse reactions at ≥ 2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.
Please see the Full Prescribing Information for OMIDRIA.
You are encouraged to report Suspected Adverse Reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Indications and Usage

OMIDRIA® is added to ophthalmic irrigating solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.

Important Safety Information

OMIDRIA must be added to irrigating solution prior to intraocular use.

OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients.
Systemic exposure to phenylephrine may cause elevations in blood pressure.
Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory drugs (NSAIDs), or have a past medical history of asthma.
The most commonly reported adverse reactions at ≥ 2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.
Please see the Full Prescribing Information for OMIDRIA.
You are encouraged to report Suspected Adverse Reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

bottom of page